MAPT and Alzheimer disease: In this proof‐of‐concept study, we report that Dyrk1 is a valid new target for AD treatment and show that its chronic inhibition reduced Aβ and tau pathology and ameliorated cognitive deficits in 3xTg‐AD mice.